Source-defined biomarker
Pharmacodynamic biomarker used in NASH clinical trials to assess efficacy and change in disease severity by providing an early indication of response to treatment
This exact source name has not been reconciled to a broader biomarker identity.
Pharmacodynamic biomarker used in NASH clinical trials to assess efficacy and change in disease severity by providing an early indication of response to treatment is a source-defined biomarker in the evidence tier "FDA qualification project". This page lists evidence by type: FDA biomarker qualification projects (1), each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA qualification project
Source-level evidence only
FDA biomarker qualification projects (1)
Shown in this order: most recent snapshot first.
| Project | DDT number | Source status | Submitter | Biomarker role |
|---|---|---|---|---|
| Pharmacodynamic biomarker used in NASH clinical trials to assess efficacy and change in disease severity by providing an early indication of response to treatment | DDT-BMQ-000131 | Project status: Under review | Perspectum Diagnostics | Pharmacodynamic |
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and assay-provider ledger.